Swayampakula Ramakanth

H.C. Wainwright Maintains Buy On Mela Sciences Following 3Q14 Report

In a research report issued this morning, H.C.

Editor Ben Weinberg — November 13, 2014, 2:33 PM EDT

H.C. Wainwright Downgrades Aeterna To Neutral Following CRL From FDA

In a research note published today, H.C.

Editor Ben Weinberg — November 6, 2014, 4:46 PM EDT

H.C. Wainwright Remains Positive On EDAP Following FDA’s Guidance

In a research report issued today, H.C.

Ben Mahaney, Editor — November 6, 2014, 3:18 PM EDT

H.C. Wainwright Maintains Buy On Aeterna Zentaris Ahead Of FDA Ruling

In a research report issued today, H.C.

Ben Mahaney, Editor — October 27, 2014, 3:38 PM EDT

H.C. Wainwright Reiterates Buy On EDAP Following 2Q14 Update

In a report issued today, H.C.

Ben Mahaney, Editor — August 28, 2014, 2:28 PM EDT

H.C. Wainwright Reiterates Buy On Aeterna Zentaris Following 2Q14 Business Update

In a report issued today, H.C.

Ben Mahaney, Editor — August 8, 2014, 1:46 PM EDT

H.C. Wainwright Reiterates Buy On Aeterna Zentaris; Sees %154 Upside

In a research report released today, H.C.

Editor Ben Weinberg — August 5, 2014, 12:46 PM EDT

EDAP: We Believe A Positive FDA Decision Is Now Unlikely, Says H.C. Wainwright

The Gastroenterology Urology Device Panel, which Wednesday reviewd EDAP TMS’s (EDAP) Ablatherm Pre Marketing Approval (PMA) application for the primary treatment of low-risk, …

Ben Mahaney, Editor — August 1, 2014, 3:50 PM EDT

EDAP: Ablatherm Has A 65-70% Chance Of A Positive Panel Vote, Says H.C. Wainwright

In a research report issued Monday, H.C.

Ben Mahaney, Editor — July 28, 2014, 1:50 PM EDT

Aeterna Zentaris Shares Are Currently Undervalued And Provide Upside, Says H.C. Wainwright

In a research report released today, H.C.

Ben Mahaney, Editor — July 17, 2014, 3:44 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts